The U.S. Food and Drug Administration today approved Vyvgart (efgartigimod) for the treatment of generalized myasthenia gravis (gMG) in adults who test positive for the anti-acetylcholine receptor (AChR) antibody.
- eTurboNews | Trends | Travel News
http://dlvr.it/SFbsd6
No comments:
Post a Comment